IGEN places 1 million shares:
This article was originally published in Clinica
Executive Summary
Gathersburg, Maryland-based IGEN has placed slightly over 1 million shares with two investment arms from the Acqua Wellington group. The transaction has raised $30 million. It will enable IGEN to continue advancing its business plan and to help fund the cost of legal proceedings against Roche. IGEN is locked in patent litigation with the Swiss worldwide diagnostics market leader over distribution rights to its ORIGEN technology. Last month, IGEN secured victory in Delaware (see Clinica No 986, p 17), but the larger Maryland case is still pending.
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.